FR25C1029I2 - Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations - Google Patents

Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations

Info

Publication number
FR25C1029I2
FR25C1029I2 FR25C1029C FR25C1029C FR25C1029I2 FR 25C1029 I2 FR25C1029 I2 FR 25C1029I2 FR 25C1029 C FR25C1029 C FR 25C1029C FR 25C1029 C FR25C1029 C FR 25C1029C FR 25C1029 I2 FR25C1029 I2 FR 25C1029I2
Authority
FR
France
Prior art keywords
bcma
antibodies
bispecific
bispecific anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR25C1029C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67515169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR25C1029(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of FR25C1029I1 publication Critical patent/FR25C1029I1/fr
Application granted granted Critical
Publication of FR25C1029I2 publication Critical patent/FR25C1029I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR25C1029C 2018-07-19 2025-07-29 Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations Active FR25C1029I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862700596P 2018-07-19 2018-07-19
US201862750968P 2018-10-26 2018-10-26
US201962793645P 2019-01-17 2019-01-17
PCT/US2019/042447 WO2020018820A1 (fr) 2018-07-19 2019-07-18 Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations

Publications (2)

Publication Number Publication Date
FR25C1029I1 FR25C1029I1 (fr) 2025-09-26
FR25C1029I2 true FR25C1029I2 (fr) 2026-03-27

Family

ID=67515169

Family Applications (1)

Application Number Title Priority Date Filing Date
FR25C1029C Active FR25C1029I2 (fr) 2018-07-19 2025-07-29 Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations

Country Status (34)

Country Link
US (3) US11384153B2 (fr)
EP (2) EP4516810A3 (fr)
JP (2) JP7319348B2 (fr)
KR (1) KR20210034032A (fr)
CN (1) CN112423785B (fr)
AU (1) AU2019307928B2 (fr)
BR (1) BR112021000186A2 (fr)
CL (1) CL2021000131A1 (fr)
CO (1) CO2021000188A2 (fr)
CY (2) CY1127721T1 (fr)
DK (1) DK3823664T3 (fr)
ES (1) ES3010285T3 (fr)
FI (2) FI3823664T3 (fr)
FR (1) FR25C1029I2 (fr)
HR (1) HRP20250199T1 (fr)
HU (2) HUE070224T2 (fr)
IL (1) IL279974B2 (fr)
LT (2) LT3823664T (fr)
MA (1) MA53168B1 (fr)
MD (1) MD3823664T2 (fr)
MX (2) MX2021000488A (fr)
MY (1) MY201816A (fr)
NL (1) NL301335I2 (fr)
NO (1) NO2025036I1 (fr)
PH (1) PH12021550031A1 (fr)
PL (1) PL3823664T3 (fr)
PT (1) PT3823664T (fr)
RS (1) RS66535B1 (fr)
SG (1) SG11202100252SA (fr)
SI (1) SI3823664T1 (fr)
SM (1) SMT202500044T1 (fr)
TW (1) TWI838389B (fr)
WO (1) WO2020018820A1 (fr)
ZA (1) ZA202100087B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102546A1 (fr) 2016-11-30 2018-06-07 The Jackson Laboratory Modèle de souris humanisée à développement amélioré de cellules immunitaires humaines innées
EP3559035A1 (fr) 2016-12-21 2019-10-30 TeneoBio, Inc. Anticorps à chaîne lourde uniquement anti-bcma
IL270894B2 (en) 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
LT4324851T (lt) 2018-07-19 2025-10-10 Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas
KR20210143246A (ko) * 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
HUE068401T2 (hu) 2019-11-11 2024-12-28 Amgen Res Munich Gmbh A BCMA elleni hatóanyagok adagolási rendje
JP7693672B2 (ja) * 2019-12-06 2025-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法
TW202144425A (zh) * 2020-04-17 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 特異性抗原結合分子，其製備方法及醫藥用途
EP4545569A3 (fr) * 2020-06-30 2025-10-08 Harbour Biomed (Shanghai) Co., Ltd Protéine de liaison ayant des structures h2l2 et hcab
US11897945B2 (en) 2020-07-01 2024-02-13 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-Bet v 1 antibodies
KR20230069181A (ko) * 2020-09-14 2023-05-18 화이자 인코포레이티드 암 치료를 위한 방법, 요법 및 용도
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
JP7905328B2 (ja) 2020-09-18 2026-08-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用
CN118878693A (zh) * 2020-11-23 2024-11-01 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
TW202246333A (zh) * 2021-01-20 2022-12-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｂｃｍａ和ｃｄ３的抗原結合分子及其醫藥用途
CA3202891A1 (fr) 2021-01-28 2022-08-04 Kara Olson Compositions et methodes de traitement du syndrome de liberation de cytokines
BR112023027006A2 (pt) * 2021-06-21 2024-03-12 BioNTech SE Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
CN120424234A (zh) * 2021-08-30 2025-08-05 上海君赛生物科技有限公司 含有膜表面结构域的多肽及其用途
EP4428156A4 (fr) 2021-12-03 2026-03-04 Shandong Simcere Biopharmaceutical Co., Ltd. Nanocorps anti-bcma et son utilisation
CA3244028A1 (fr) * 2021-12-22 2023-06-29 The Jackson Laboratory Modèles murins humanisés
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN117003871A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
CA3252182A1 (fr) 2022-05-18 2023-11-23 Regeneron Pharmaceuticals, Inc. Molécules multispécifiques de liaison à l'antigène qui se lient à cd38 et 4-1bb et utilisations associées
WO2023236889A1 (fr) 2022-06-06 2023-12-14 山东先声生物制药有限公司 Anticorps multi-spécifique ciblant bcma, gprc5d et lymphocytes t et son application
AR129560A1 (es) 2022-06-08 2024-09-04 Tidal Therapeutics Inc Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
CN115368466A (zh) * 2022-07-19 2022-11-22 合肥天港免疫药物有限公司 双特异性抗体及其应用
IL319818A (en) 2022-10-10 2025-05-01 Regeneron Pharma Methods for reducing alloantibody levels in patients requiring solid organ transplantation
CN117126280B (zh) * 2022-12-06 2024-03-29 成都赛恩吉诺生物科技有限公司 具有亲水性氨基酸残基的抗人bcma纳米抗体及car-t和应用
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
EP4719352A1 (fr) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Formulations et compositions de nanoparticules lipidiques
EP4725970A1 (fr) 2023-06-06 2026-04-15 Fortvita Biologics Inc. Préparation et utilisation d'anticorps trispécifique anti-gprc5d/bcma/cd3
TW202517293A (zh) 2023-07-07 2025-05-01 美商再生元醫藥公司 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物
EP4777540A1 (fr) 2023-09-13 2026-07-22 Juno Therapeutics, Inc. Polythérapies comprenant une thérapie cellulaire exprimant un car ciblant gprc5d, méthodes et utilisations associés
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
CN122349420A (zh) 2023-12-04 2026-07-07 山东先声再明生物制药有限公司 一种多特异性抗体的组合物及其制备方法和应用
WO2025131077A1 (fr) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 Anticorps multi-spécifique anti-cd3 et son utilisation
WO2025160340A2 (fr) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Immunosuppression combinée pour inhiber une réponse immunitaire et pour permettre une administration et une réadministration d'immunogène
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
TW202543581A (zh) 2024-02-12 2025-11-16 美商艾伊拉醫療公司 遞送組成物
WO2025184567A1 (fr) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Procédés et compositions pour redosage d'un aav à l'aide d'un anticorps antagoniste anti-cd40 pour supprimer une réponse d'anticorps anti-aav hôte
US20250381150A1 (en) 2024-03-08 2025-12-18 Genzyme Corporation Lipid nanoparticles
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
TW202611075A (zh) 2024-05-13 2026-03-16 美商再生元醫藥公司 以雙特異性BCMAxCD3抗體治療輕鏈類澱粉變性症之方法
WO2025244973A1 (fr) 2024-05-20 2025-11-27 Regeneron Pharmaceuticals, Inc. Méthodes de traitement d'un myélome multiple avec des anticorps bispécifiques bcma x cd3
WO2026006495A1 (fr) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anticorps anti-wt1/hla-a2 et ses utilisations
WO2026006492A2 (fr) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anticorps anti-prame/hla-a2 et leurs utilisations
US20260014252A1 (en) 2024-07-11 2026-01-15 Regeneron Pharmaceuticals, Inc. GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof
WO2026059920A1 (fr) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du myélome multiple avec des inhibiteurs de bcma en combinaison avec des inhibiteurs de pd1/pd-l1
WO2026059917A1 (fr) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du myélome multiple faisant appel à des inhibiteurs du bcma associés à des inhibiteurs du protéasome
WO2026059923A1 (fr) 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du myélome multiple mettant en oeuvre des inhibiteurs du bcma en association avec un immunomodulateur
US20260070998A1 (en) 2024-09-10 2026-03-12 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with cd38 inhibitors
US20260158137A1 (en) 2024-09-10 2026-06-11 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors
WO2026072671A1 (fr) 2024-09-24 2026-04-02 City Of Hope Procédés utilisant des virus oncolytiques exprimant le bcmat et thérapies ciblées anti-bcma
WO2026072557A2 (fr) 2024-09-24 2026-04-02 Genzyme Corporation Nanoparticules lipidiques et lipides cationiques ionisables, leurs procédés de synthèse et méthodes d'utilisation
WO2026072709A1 (fr) 2024-09-25 2026-04-02 Orna Therapeutics, Inc. Récepteurs antigéniques chimériques ciblant bcma
WO2026112559A1 (fr) 2024-11-25 2026-05-28 Genzyme Corporation Lipides cationiques ionisables et nanoparticules lipidiques, et leurs procédés de synthèse et d'utilisation
WO2026142951A1 (fr) 2024-12-23 2026-07-02 Genzyme Corporation Système pharmaceutique
WO2026151982A1 (fr) 2025-01-10 2026-07-16 Regeneron Pharmaceuticals, Inc. Méthodes de traitement d'allergie alimentaire par administration d'un antagoniste d'il-4r et d'un agent de ciblage de bcma

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HK1043608B (en) 1999-08-17 2007-12-07 Biogen Ma Inc. Baff receptor (bcma), an immunoregulatory agent
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1355919B1 (fr) 2000-12-12 2010-11-24 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
DE10206325A1 (de) 2002-02-14 2003-09-04 Medinnova Ges Med Innovationen Ummantelter Mikroorganismus
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
EP3974453A3 (fr) 2010-11-16 2022-08-03 Amgen Inc. Agents et procédés pour traiter les maladies en corrélation avec l'expression bcma
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
EP2714737A1 (fr) 2011-05-27 2014-04-09 Glaxo Group Limited Protéines de liaison à bcma (cd269/tnfrsf17)
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2914628A1 (fr) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin Anticorps qui se lie à cd269 (bcma) pouvant être utilisé dans le traitement de maladies des cellules plasmatiques comme le myélome multiple et les maladies auto-immunes
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP2762497A1 (fr) 2013-02-05 2014-08-06 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
EP2762496A1 (fr) 2013-02-05 2014-08-06 EngMab AG Procédé pour la sélection d'anticorps contre BCMA
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US20180112384A1 (en) 2013-12-30 2018-04-26 Craig Rothleitner Drainage treatment system
BR112016024546A2 (pt) 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
EP3172231B1 (fr) 2014-07-24 2021-05-05 Bluebird Bio, Inc. Récepteurs de l'antigène chimérique bcma
EP2982692A1 (fr) 2014-08-04 2016-02-10 EngMab AG Anticorps bispécifiques contre la CD3epsilon et BCMA
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
EP3029068A1 (fr) 2014-12-03 2016-06-08 EngMab AG Anticorps bispécifiques contre du CD3epsilon et BCMA pour utilisation dans le traitement de maladies
CN113698497A (zh) 2014-12-05 2021-11-26 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
HRP20210582T1 (hr) 2014-12-05 2021-09-03 Memorial Sloan Kettering Cancer Center Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向ｂ細胞成熟抗原之嵌合型抗原受體類
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
JP6901493B2 (ja) 2015-11-13 2021-07-14 アメリカ合衆国 抗ｂｃｍａポリペプチド及びタンパク質
ES2913208T3 (es) 2015-12-01 2022-06-01 Glaxosmithkline Ip Dev Ltd Tratamientos de combinación y usos y métodos de los mismos
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
UA126657C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
MA44254A (fr) 2016-02-17 2018-12-26 Seattle Genetics Inc Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
NZ746700A (en) 2016-04-01 2023-04-28 Kite Pharma Inc Bcma binding molecules and methods of use thereof
US12048718B2 (en) 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
EP3481410A2 (fr) 2016-07-08 2019-05-15 Paul C. Tumeh Compositions et méthodes de traitement pour l'immunothérapie du cancer
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
WO2018075359A1 (fr) 2016-10-18 2018-04-26 Boger Henry William Transfert d'énergie sans fil destiné à une commande de processus
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
WO2018099539A1 (fr) 2016-11-29 2018-06-07 Horst Lindhofer Combinaison d'anticorps multifonctionnels de redirection de lymphocytes (t) avec des modulateurs de point de contrôle immunitaires et leurs utilisations
EP3559035A1 (fr) 2016-12-21 2019-10-30 TeneoBio, Inc. Anticorps à chaîne lourde uniquement anti-bcma
EP3572427B1 (fr) 2017-01-23 2025-06-25 CRAGE medical Co., Limited Anticorps ciblant bcma et son utilisation
WO2018145075A1 (fr) 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour augmenter la signalisation de récepteurs médiée par des anticorps
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615068A1 (fr) 2017-04-28 2020-03-04 Novartis AG Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
MA48763A (fr) 2017-05-05 2020-04-08 Amgen Inc Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
UA126813C2 (uk) 2017-08-01 2023-02-08 Медімм'Юн, Ллк Моноклональний кон’югат антитіло-лікарський засіб до bcma
WO2019066435A2 (fr) 2017-09-29 2019-04-04 재단법인 목암생명과학연구소 Anticorps anti-bcma ayant une affinité élevée pour bcma et composition pharmaceutique pour le traitement du cancer, comprenant celui-ci
CA3078969A1 (fr) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Proteines trispecifiques et methodes d'utilisation
CN107827989A (zh) 2017-10-18 2018-03-23 银丰生物工程集团有限公司 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用
ES2968880T3 (es) 2018-02-01 2024-05-14 Nanjing Iaso Biotechnology Co Ltd Receptor de antígeno quimérico (CAR) que se une a BCMA, y usos del mismo
BR112020023508A2 (pt) * 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
KR20210143246A (ko) * 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용

Also Published As

Publication number Publication date
JP2023134728A (ja) 2023-09-27
IL279974B1 (en) 2025-03-01
CY1127721T1 (el) 2026-02-25
US20220306758A1 (en) 2022-09-29
PH12021550031A1 (en) 2021-09-20
SMT202500044T1 (it) 2025-03-12
MX2021000488A (es) 2021-04-12
JP2021531005A (ja) 2021-11-18
JP7586974B2 (ja) 2024-11-19
AU2019307928B2 (en) 2025-09-25
US20200024356A1 (en) 2020-01-23
MA53168B1 (fr) 2025-03-28
WO2020018820A1 (fr) 2020-01-23
MY201816A (en) 2024-03-19
US12258412B2 (en) 2025-03-25
FR25C1029I1 (fr) 2025-09-26
HRP20250199T1 (hr) 2025-04-11
HUS2500032I1 (hu) 2025-09-28
MX2025005515A (es) 2025-06-02
AU2019307928A1 (en) 2021-02-11
PL3823664T3 (pl) 2025-03-17
KR20210034032A (ko) 2021-03-29
EP4516810A2 (fr) 2025-03-05
TWI838389B (zh) 2024-04-11
ES3010285T3 (en) 2025-04-02
TW202019966A (zh) 2020-06-01
US11384153B2 (en) 2022-07-12
LT3823664T (lt) 2025-02-25
RS66535B1 (sr) 2025-03-31
CL2021000131A1 (es) 2021-07-02
EP3823664A1 (fr) 2021-05-26
EP4516810A3 (fr) 2025-07-16
FIC20253006I1 (fi) 2025-08-14
CA3107126A1 (fr) 2020-01-23
FI3823664T3 (fi) 2025-03-04
JP7319348B2 (ja) 2023-08-01
BR112021000186A2 (pt) 2021-08-10
EP3823664B1 (fr) 2025-01-08
CY2025020I2 (el) 2026-02-25
MA53168A (fr) 2021-05-26
CN112423785B (zh) 2025-03-04
HUE070224T2 (hu) 2025-05-28
NO2025036I1 (no) 2025-08-07
PT3823664T (pt) 2025-01-24
IL279974B2 (en) 2025-07-01
IL279974A (en) 2021-03-01
CY2025020I1 (el) 2026-02-25
SI3823664T1 (sl) 2025-03-31
CO2021000188A2 (es) 2021-01-18
US20260008862A1 (en) 2026-01-08
SG11202100252SA (en) 2021-02-25
NL301335I2 (nl) 2025-09-10
CN112423785A (zh) 2021-02-26
ZA202100087B (en) 2025-07-30
DK3823664T3 (da) 2025-02-17
LTPA2025526I1 (fr) 2025-07-25
MD3823664T2 (ro) 2025-06-30

Similar Documents

Publication Publication Date Title
FR25C1029I1 (fr) Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations
MA54539A (fr) Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
MA52970A (fr) Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations
EP3891187A4 (fr) Anticorps bispécifiques anti-pd-l1/anti-4-1bb et leurs utilisations
MA54540A (fr) Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
MA52771A (fr) Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3833693A4 (fr) Anticorps bispécifiques anti-pd-l1/anti-lag3 et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3918323A4 (fr) Anticorps anti-gal3 et leurs utilisations
EP3898691A4 (fr) Anticorps trem2 et leurs utilisations
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
EP3897719A4 (fr) Anticorps bispécifiques clivables par la protéase et utilisations associées
EP3661555A4 (fr) Anticorps bispécifiques et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
EP3966252A4 (fr) Anticorps anti-cd137 humanisés et leurs utilisations
EP4048699A4 (fr) Anticorps multispécifiques anti-pd-l1/anti-b7-h3 et leurs utilisations
EP3894440A4 (fr) Anticorps anti-il-27 et leurs utilisations
EP3962954A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations
EP3755716A4 (fr) Anticorps anti-pd-1 et leurs utilisations
MA52235A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3755714A4 (fr) Anticorps anti-angiopoïétine-2 et leurs utilisations